Associations of peripheral neuropathy with patient-reported outcome (PRO) measures in women with breast cancer: from pre-chemotherapy to three or more years post chemotherapy
Supportive Care in Cancer · 2026-12 · 34 (12)
DOI: 10.1007/s00520-026-11455-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Supportive Care in Cancer, online erschienen am 16.11.2026. Verfasst von K A Nyrop und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. kirsten_nyrop@med.unc.edu. Hauptthemen laut MEDLINE: Breast Neoplasms, Patient Reported Outcome Measures, Quality of Life, Peripheral Nervous System Diseases. Die Arbeit nennt 66 Literaturangaben. Gefördert von: Breast Cancer Research Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
This study investigates numbness/tingling in hands and feet (peripheral neuropathy/PN) at long-term follow-up (LTFU) and quality of life (QoL) in women treated with chemotherapy for non-metastatic breast cancer.
Methods
Women with stage I–III breast cancer were consented and responded to questionnaires prior to and during chemotherapy treatment and were then reconsented for questionnaires three or more years after treatment completion. Descriptive statistics for clinical and demographic characteristics, patient-reported outcome (PRO) measures, and patient-reported symptoms (PRO-CTCAE) are provided. Univariable and multivariable modified Poisson modeling, adjusting for age and body mass index (BMI), was conducted to describe PN and QoL measures at LTFU.
Results
In a sample of 108 patients, average age at breast cancer diagnosis was 54 (range 24–77) and 27% non-White. At LTFU, 37% reported no PN symptoms and 63% reported mild, moderate, or severe/very severe symptoms. In adjusted multivariable modeling, the following pre-chemotherapy variables were associated with PN symptoms at LTFU: older age (RR 1.02), higher BMI (RR 1.02), and FACT-General measures for Physical, Social/Family, and Emotional well-being (RR 0.96 to 0.99). PRO-CTCAE symptoms assessed during chemotherapy were similarly associated with PN at LTFU: arm/leg swelling (RR 1.96), general pain (RR 1.71), myalgia (RR 1.95), and numbness/tingling in hands/feet (RR 1.63). In multivariable analysis of variables assessed at LTFU , significant associations were again similar to those observed for variables assessed pre- and during chemotherapy treatment.
Conclusion
Patient-reported outcome measures assessed pre- and during chemotherapy treatment can signal increased risk for PN symptoms at LTFU. Even mild PN at FU can have associations with QoL and function. These findings underscore the need for rigorous monitoring of PN symptoms and timely interventions from pre-treatment through long-term follow-up, when patients are scheduled for annual or routine clinic visits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. kirsten_nyrop@med.unc.edu.
- University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Förderung
- Breast Cancer Research Foundation
Zitieren
APA
Nyrop, K. A., Wardell, A. C., Deal, A. M., Ross, A., Grahn, O., & Muss, H. B. (2026). Associations of peripheral neuropathy with patient-reported outcome (PRO) measures in women with breast cancer: from pre-chemotherapy to three or more years post chemotherapy. Supportive Care in Cancer, 34(12). https://doi.org/10.1007/s00520-026-11455-7
Vancouver
Nyrop KA, Wardell AC, Deal AM, Ross A, Grahn O, Muss HB. Associations of peripheral neuropathy with patient-reported outcome (PRO) measures in women with breast cancer: from pre-chemotherapy to three or more years post chemotherapy. Supportive Care in Cancer. 2026;34(12). doi:10.1007/s00520-026-11455-7
BibTeX
@article{Nyrop2026,
author = {Nyrop, K A and Wardell, A C and Deal, A M and Ross, A and Grahn, O and Muss, H B},
title = {Associations of peripheral neuropathy with patient-reported outcome (PRO) measures in women with breast cancer: from pre-chemotherapy to three or more years post chemotherapy},
journal = {Supportive Care in Cancer},
year = {2026},
volume = {34},
number = {12},
doi = {10.1007/s00520-026-11455-7}
}
EUVIMED